A century-old drug costing just $4 a month slashes insulin needs by 12% in type 1 diabetes patients, upending long-held medical assumptions and hinting at simpler lives ahead.
Story Snapshot
- Garvan Institute RCT shows metformin cuts insulin use without fixing resistance or blood sugar.
- 40 adults tested over 6 months; first solid evidence challenging off-label myths.
- Up to 13,000 Australians already use it anecdotally for relief from insulin burden.
- Researchers probe mystery mechanism while patients eye easier management.
- Affordable generic challenges pricey insulin dominance in type 1 care.
Garvan Trial Reveals Metformin’s Surprise Effect
Garvan Institute researchers Dr. Snaith and Prof. Jerry Greenfield led the world’s first randomized controlled trial on metformin in adult type 1 diabetes patients. They enrolled 40 participants for six months, comparing metformin against placebo. Results showed participants needed 12% less insulin to stabilize blood sugars. This outcome defied expectations that metformin counters insulin resistance in type 1, as it does in type 2. The trial, published in November 2025, marks a pivotal shift.
Metformin’s Long History Meets Type 1 Reality
Metformin exists in forms for about 100 years, serving as the first-line type 2 diabetes treatment to combat insulin resistance. Doctors prescribed it off-label to up to 10% of type 1 patients globally, including 13,000 Australians, based on anecdotes. Type 1 diabetes demands lifelong insulin after beta-cell destruction, creating burdens like hypoglycemia risks and mental fatigue. Prior small studies hinted at benefits, but lacked rigorous proof until Garvan’s RCT disproved the resistance hypothesis.
Researchers Challenge Assumptions with Hard Data
Dr. Snaith stated participants on metformin used 12% less insulin than placebo users, calling it an important result for simplifying treatment. Prof. Greenfield noted metformin’s mechanism remains unknown, even after a century. The team expected insulin sensitivity gains but found none, nor changes in blood sugar or HbA1c. This disconnect fuels ongoing mechanism studies.
Stakeholders Drive Research and Patient Relief
Garvan Institute sponsored the trial, collaborating with UNSW Sydney for academic rigor. Dr. Snaith aimed to validate off-label use through cheap drugs. Prof. Greenfield investigates metformin’s novel action in type 1. Patients seek reduced insulin loads to ease daily struggles. Pharma shows minimal interest due to metformin’s generic status and low profits. Regulators like TGA and FDA may review for approvals, while groups like Breakthrough T1D influence guidelines.
This cheap drug could help people with type 1 diabetes use less insulin | ScienceDaily – https://t.co/crFZ8Ajz9V #GoogleAlerts
— James Myers (@JamesMy56782210) April 17, 2026
Implications Reshape Type 1 Management
Short-term, off-label metformin use may rise, offering 12% less insulin dosing to cut physical and mental burdens. Long-term, clarified mechanisms could integrate it into guidelines, slashing costs at $4 monthly versus insulin expenses. Patients gain simpler regimens with lower hypoglycemia risks. Clinicians secure evidence-based options. Global access thrives on generic availability, aiding low-resource areas without policy overhauls. This contrasts high-cost stem cell trials curing few.
Sources:
How a cheap, century-old drug can improve life with type 1 diabetes
Common drug found to reduce insulin needs in type 1 diabetes
Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes – PMC
